NYSE · Healthcare
ZIMMER BIOMET HOLDINGS, INC. (ZBH)
As-reported financials and recent SEC filings for ZIMMER BIOMET HOLDINGS, INC., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$8.23B
Net income
$705.1M
Net margin
8.6%
Diluted EPS
$3.55
ROE
5.5%
P/E (TTM)
24.1×
Market cap
$18.01B
Debt / equity
0.5×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $8.23B | $7.68B | $7.39B | $6.94B | $6.83B |
| Gross profit | $5.74B | $5.49B | $5.31B | $4.92B | $4.87B |
| Operating income | $1.10B | $1.29B | $1.28B | $696.3M | $860.3M |
| Net income | $705.1M | $903.8M | $1.02B | $231.4M | $401.6M |
| Diluted EPS | $3.55 | $4.43 | $4.88 | $1.10 | $1.91 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
1442026-06-24
View on EDGAR →42026-06-03
View on EDGAR →42026-06-02
View on EDGAR →1442026-05-29
View on EDGAR →42026-05-27
View on EDGAR →42026-05-27
View on EDGAR →42026-05-27
View on EDGAR →42026-05-27
View on EDGAR →Go deeper on ZBH
Search ZIMMER BIOMET HOLDINGS, INC.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.